Phase I study of artificial tumor-antigens (GPC3/AFP/MAGE1) pulsed dendritic cell vaccination for patients with hepatocellular carcinoma

Phase 1

• Conditions: Hepatocellular carcinoma

• Registration Number: JPRN-UMIN000011854
• Lead Sponsor: Kitasato Institute Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-01
• Study Completion: 2014-06-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Not provided

Exclusion Criteria

1) Sever hemorrhagic diathesis PT <50% APTT >60% Doctors judgment of severe bleeding tendency 2) Carrier of HBV, HTLV-1, HIV and so on 3) Severe comorbidity of heart disease (NYHA classIII, IV) 4) Intolerable cardiovascular disease for the apheresis 5) Past history of autoimmune disease (PSS, Sjogren syndrome, ITP, MS, RA etc.) 6) During treatment with immunosuppressive agents 7) Severe allergy with penicillin or picibanil 8) Pantients with adverse events of CTCAE v4.0 >= grade 3 of nonhematological toxicity, or >= grade 4 of hematological toxicity 9) Pregnancy, nursing women 10) Male hope to impregnate 11) Patients whom doctors judged inadequate to the enrollment of this study by other reasons

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse events